Pharma Focus Asia

TriLink BioTechnologies to Open Drug Production Facility in USA

Introduction:

TriLink BioTechnologies plans to open a state-of-the-art facility dedicated to late-phase mRNA drug substance production in the United States.

Features: 

The 32,000-square-foot facility is meticulously crafted for mRNA manufacturing, serving as a dedicated hub to assist late-phase drug developers, spanning from phase 2 trials to commercialisation, with its robust mRNA manufacturing capabilities.

The facility is equipped with separate Grade C cleanroom suites dedicated to mRNA manufacturing, offering expanded mRNA capacity ranging from 1g to over 100g per batch. 

Additionally, it provides comprehensive in-house analytical services and laboratory space for conducting on-site quality control testing. 

The manufacturing suites are equipped with cutting-edge equipment and poised to meet late-phase manufacturing requirements.

This facility is anticipated to drive significant advancements in life-saving mRNA therapeutics.

This new facility advances the field by playing a pivotal role in advancing mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines. 

The opening is anticipated to drive the advancement of mRNA-based medicine for an expanding array of indications.

Specifications:

Name    TriLink BioTechnologies
Type       New Construction

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference